-
- 1800 2010
- EN
News
Array
(
[0] => stdClass Object
(
[id] => 1395
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 603924137_1486168513515857_3858940485546585452_n.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-12-25
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-12-25 13:18:45
[updated_time] => 2026-01-14 15:26:26
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Eurofins-GENTIS-pioneers-the-deployment-of-Next-generation-sequencing-technology-MiSeq-i100-Plus-in-Vietnam
[title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in Vietnam
[description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirms Eurofins GENTIS’s long-term commitment to continuously advancing genetic diagnostic capabilities and aligning with the highest standards of modern global medicine.
[content] => The MiSeq i100 Plus is Illumina’s newest benchtop sequencer — from the world’s leading brand in NGS technology. More than a conventional sequencing instrument, the MiSeq i100 Plus represents a significant leap forward in performance, speed, and accuracy, meeting the ever-growing demands of clinical and research laboratories.
Eurofins GENTIS’s pioneering adoption of this system clearly reflects its strategic, long-term investment vision to deliver the most advanced genetic testing solutions to the community.
One of the most outstanding advantages of the MiSeq i100 Plus is its exceptional sequencing speed. By leveraging advanced chemistry and an optimized workflow, the system significantly shortens run times, enabling many NGS-based tests to deliver same-day results while maintaining high accuracy and data reliability.
This capability is particularly critical in clinical settings requiring rapid decision-making, allowing physicians to implement timely and effective treatment strategies.
In addition to speed, the MiSeq i100 Plus features a “Touch & Run” plug-and-play design, simplifying complex technical procedures. The integrated reagent cartridge minimizes manual preparation steps, thereby reducing human error and enhancing consistency between runs. With its user-friendly design and high level of automation, Eurofins GENTIS’s technical team can operate the system smoothly and reliably, while dedicating greater focus to in-depth analysis and rigorous quality control.
The system incorporates Illumina’s proprietary XLEAP-SBS™ technology, delivering superior read quality and significantly improving the accuracy and reliability of sequencing data. This allows the platform to precisely detect and analyze complex genetic variants, meeting the stringent requirements of modern genetic testing across both clinical and research applications.
With installation, technology transfer, and continuous technical support from Mitalab, Eurofins GENTIS is maximizing the capabilities of the MiSeq i100 Plus across multiple critical fields of medicine and molecular biology.
NGS enables accurate analysis of chromosomal abnormalities and pathogenic genetic variants, significantly enhancing reproductive health counseling and care, and helping many families realize their dream of parenthood.
The MiSeq i100 Plus plays a pivotal role in early detection of cancer-related genetic mutations, comprehensive tumor genomic profiling, and the development of targeted treatment regimens.
This forms the foundation of precision medicine, where each patient receives therapies tailored to their unique genetic profile — improving treatment outcomes and quality of life.
The system expands capabilities in diagnosing rare diseases and conducting high-sensitivity microbial studies, enabling the detection of novel or hard-to-identify pathogens beyond the limits of conventional methods.
These advancements contribute not only to clinical effectiveness but also to biomedical research and healthcare development in Vietnam.
Becoming the first organization in Vietnam to deploy the MiSeq i100 Plus once again reinforces Eurofins GENTIS’s leadership position in genetic testing and diagnostics.
This milestone reflects not only technological achievement but also the company’s strategic vision, deep professional expertise, and long-term commitment to bringing the world’s most advanced medical technologies closer to the Vietnamese community.
Looking ahead, Eurofins GENTIS will continue making strong investments in technological infrastructure, human resources, and international collaboration — partnering with the healthcare sector to elevate diagnostic quality, advance personalized medicine, and safeguard public health.
[content_more] =>
[meta_title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in
[meta_description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirm
[meta_keyword] => GENTIS
[thumbnail_alt] =>
[post_id] => 1395
[category_id] => 4
)
[1] => stdClass Object
(
[id] => 1394
[id_crawler] =>
[category_product] => NULL
[thumbnail] => thong-bao-eurofins-gentis-lam-việc-xuyen-tết-dương-lịch-2026.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-12-25
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-12-25 08:41:05
[updated_time] => 2026-01-14 15:16:21
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Eurofins-GENTIS-operates-throughout-New-Year’s-day-2026
[title] => Eurofins GENTIS operates throughout New Year’s day 2026
[description] => As the vibrant atmosphere of the new year approaches, Eurofins GENTIS would like to respectfully inform our valued Customers and Partners of our official working schedule for New Year’s Day – January 1, 2026. In order to best meet the growing demands for testing services, consultation, and technical support, Eurofins GENTIS will continue operating throughout the New Year holiday, ensuring that all services remain uninterrupted, timely, and efficient.
[content] => Eurofins GENTIS understands that New Year is a period when demand for medical testing — especially genetic testing, DNA paternity testing, NIPT for pregnant women, and advanced analytical services — increases significantly.
Therefore, maintaining continuous operations not only reflects our strong sense of responsibility, but also reaffirms our commitment to safeguarding community health and supporting our customers whenever they need us.
Eurofins GENTIS – Always ready to serve during New Year’s 2026
With the motto “Serving with Quality”, Eurofins GENTIS will operate normally on January 1, 2026, including:
- Receiving test samples directly in Hanoi and Ho Chi Minh City
- Providing remote consultation via hotline 1800 2010
- Processing and delivering test results according to standard procedures
- Answering all inquiries related to genetic and gene testing
Our continuous operation during the public holiday demonstrates the collective effort of the entire Eurofins GENTIS system to deliver seamless, uninterrupted service.
Even on holidays, our team of experts, technicians, and customer care staff remain fully available to provide fast, accurate, and dedicated support.
Enhancing service quality – dedicated care even during the holiday
Beyond ensuring uninterrupted operations, Eurofins GENTIS remains firmly committed to strict quality standards across all services.
As a member of the Eurofins Group — one of the world’s leading testing corporations — we apply internationally recognized quality management systems, ensuring high-accuracy results and optimized turnaround times.
Among the most in-demand services during the year-end period are:
NIPT – Non-Invasive prenatal testing
NIPT services at Eurofins GENTIS are conducted in CAP-accredited laboratories, the global gold standard for clinical laboratory quality.
This allows expectant mothers to confidently assess fetal chromosomal abnormality risks and safeguard their pregnancy journey for the coming year.
DNA paternity testing
Demand for parent–child DNA testing increases toward year-end.
Eurofins GENTIS provides highly accurate, strictly confidential services with flexible turnaround times suitable for both personal consultation and legal purposes.
Molecular genetic testing – Solutions for treatment & disease monitoring
Through genetic and gene testing, Eurofins GENTIS supports clients in building proactive, effective healthcare plans.
Across all services — even during public holidays — we strictly follow international standards, meeting the highest expectations of our customers and partners.
Customer appreciation – A meaningful journey together
As 2025 draws to a close, Eurofins GENTIS reflects on a year of remarkable progress: launching advanced services, improving processes, upgrading operational systems, and expanding professional collaborations.
Most importantly, we are deeply honored by the trust of hundreds of thousands of customers and partners nationwide.
On the occasion of New Year 2026, we extend our heartfelt thanks to:
- Our valued customers for their continued trust
- Our partners for their enduring cooperation
- Our dedicated staff for their tireless efforts throughout the year
Your support empowers Eurofins GENTIS to continue pursuing our mission:
Enhancing the intellectual and physical well-being of the Vietnamese people.
We look forward to remaining your trusted companion in healthcare for individuals, families, and communities in 2026.
Holiday support contact information
For timely assistance during the New Year holiday, please contact:
Toll-free Hotline: 1800 2010 (including January 1, 2026)
Or visit our offices:
Hanoi: 3rd Floor, V+ Commercial Center, 505 Minh Khai, Vinh Tuy Ward, Hanoi
Ho Chi Minh City: 8/24 Nguyen Dinh Khoi, Tan Son Nhat Ward, Ho Chi Minh City
Our professional consultants and technicians are always ready to assist with sample reception, consultation, and result delivery, ensuring maximum convenience for customers during the holiday.
New year wishes – A peaceful and radiant beginning
New Year’s Day is not only a brief holiday but also a meaningful milestone marking a fresh start.
On this occasion, Eurofins GENTIS sincerely wishes our Customers and Partners:
- A prosperous and successful 2026
- Peace of mind and strong health
- Abundant positive energy to conquer new goals
We believe that through mutual trust and sustainable partnership, Eurofins GENTIS and our Customers/Partners will create a brilliant, successful, and inspiring 2026 together.
[content_more] => [meta_title] => Eurofins GENTIS operates throughout New Year’s day 2026 [meta_description] => As the vibrant atmosphere of the new year approaches, Eurofins GENTIS would like to respectfully inform our valued Customers and Partners of our official working schedule for New Year’s Day – January 1, 2026. In order to best meet the growing demands for [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1394 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1393 [id_crawler] => [category_product] => NULL [thumbnail] => dsc09793.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-12-18 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-18 09:02:36 [updated_time] => 2025-12-18 11:21:18 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Preimplantation-genetic-testing-A-key-to-improving-IVF-success-and-protecting-future-generations [title] => Preimplantation genetic testing: A key to improving IVF success and protecting future generations [description] => In recent years, in vitro fertilization (IVF) has become a vital solution helping tens of thousands of Vietnamese couples realize their dream of parenthood. [content] =>Each year, approximately 50,000 IVF cycles are performed in Vietnam, making the country one of the fastest-growing IVF markets in the region. However, alongside this growth come increasingly evident challenges: how to improve success rates, reduce the number of embryo transfers, optimize treatment costs, and—most importantly—ensure the long-term birth of healthy babies. Advanced genetic solutions are playing a pivotal role, laying the foundation for modern, precise, and sustainable reproductive medicine. IVF success rates vary by center and patient age; they are commonly reported at around 40–50% in younger patient groups and decline significantly with increasing maternal age, as well as other influencing factors such as oocyte and sperm quality, endometrial conditions, and embryo quality.
Preimplantation Genetic Testing (PGT) has become one of the most important tools for enhancing the quality of IVF treatment. PGT enables genetic evaluation of embryos prior to uterine transfer, thereby supporting the selection of embryos with high implantation potential and reducing the risk of genetic abnormalities. At EUROFINS GENTIS, a comprehensive PGT testing system—including PGT-A, PGT-SR, PGT-M, PGT-NEXT, and PGT-UPGRADE—is implemented in an integrated manner, providing physicians and patients with stronger scientific evidence to select optimal embryos, minimize risks, and improve IVF success rates.
PGT-M – Protecting future generations from monogenic genetic disorders
In addition to chromosomal abnormalities, monogenic genetic disorders continue to silently affect the health and happiness of many Vietnamese families. These conditions are often detected only after birth, leading to long-term treatment burdens and significantly impacting the quality of life of families and society as a whole.
Prof. Dr. Nguyen Dinh Tao (Chairman of Hanoi Assisted Reproduction) has highlighted PGT-M at EUROFINS GENTIS as a pioneering solution in early genetic disease prevention strategies. He noted that PGT-M enables accurate detection of known disease-causing mutations identified in parents or within families, allowing for the screening and selection of unaffected embryos prior to transfer. A key strength of PGT-M at EUROFINS GENTIS lies in its closed-loop and highly individualized process, which includes in-depth genetic counseling, identification of disease-related mutations, tailored test strategy design, and embryo genetic analysis using next-generation sequencing (NGS) technology. This solution can be applied to a wide range of genetic disorders, including rare diseases, opening opportunities for healthy childbirth among high-risk couples. Beyond its clinical value in establishing pregnancies unaffected by specific inherited traits—such as known pathogenic variants carried by one or both parents—PGT-M also helps reduce long-term treatment burdens, lower societal healthcare costs, and improve overall population health.
PGT-AI – AI breakthroughs in reproductive genetics
Alongside rapid advances in digital technology, artificial intelligence (AI) and bioinformatics are driving profound changes in reproductive medicine. Beyond genetic data analysis alone, AI enables the integration of multiple data sources—such as embryo imaging, molecular biology data, and clinical factors—thereby generating more accurate predictive models of embryo implantation potential and developmental outcomes.
Speaking at the HASAM 2025 conference, Dr. Pham Dinh Minh (R&D Director, EUROFINS GENTIS) introduced a new test researched and piloted by EUROFINS GENTIS: PGT-AI (icOne)—an advanced AI algorithm certified by the FDA, enabling in-depth analysis of embryo genetic data using modern machine learning platforms. This technology overcomes limitations of traditional PGT methods and supports more precise and personalized clinical decision-making for each patient.
Dr. Minh further noted that EUROFINS GENTIS is currently the exclusive partner implementing PGT-AI (icOne) in Vietnam, marking a significant milestone in bringing world-leading medical technologies closer to domestic patients. The combination of AI, bioinformatics, and the extensive expertise of specialist teams has enhanced IVF effectiveness while optimizing treatment costs and patient experience.
International quality management systems – The foundation for PGT accuracy
In reproductive genetics, particularly PGT testing, quality management systems play a decisive role in ensuring accuracy and reliability of results, directly influencing embryo selection, IVF treatment outcomes, and the future of each family. According to Dr. Nguyen Quang Vinh (Laboratory Director, EUROFINS GENTIS): “The comprehensive quality management system at EUROFINS GENTIS is built and operated in accordance with strict international standards such as ISO 15189, CAP, and CLSI. This ensures standardization across the entire PGT testing workflow—from receiving embryo biopsy samples, DNA processing, NGS and bioinformatics data analysis, to final reporting. Rigorous control at every step not only minimizes technical errors and ensures consistency and reproducibility of results, but also enhances safety, data security, and traceability, thereby supporting more accurate clinical decision-making.”
Together with internationally accredited laboratories, strict DNA contamination control environments, and highly experienced experts, EUROFINS GENTIS maintains high reliability in PGT testing while establishing a solid foundation for implementing advanced technologies such as PGT-AI—contributing to improved IVF outcomes and strengthening the trust of IVF centers and patients nationwide.
Accompanying the journey to parenthood
Guided by science, technology, and quality, EUROFINS GENTIS not only provides advanced genetic testing services but also serves as a trusted partner to IVF centers and Vietnamese families on their journey toward parenthood. Through the application of modern genetic technologies, EUROFINS GENTIS is steadily contributing to higher IVF success rates, early prevention of genetic diseases, and the sustainable development of reproductive medicine in Vietnam.
[content_more] => [meta_title] => Preimplantation genetic testing: A key to improving IVF success and protecting future generations [meta_description] => Preimplantation Genetic Testing (PGT) has become one of the most important tools for enhancing the quality of IVF treatment. PGT enables genetic evaluation of embryos prior to uterine transfer, thereby supporting the selection of embryos with high implant [meta_keyword] => GENTIS,PGT [thumbnail_alt] => [post_id] => 1393 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1392 [id_crawler] => [category_product] => NULL [thumbnail] => 596067328_1263300952501760_1825096505615856739_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-11-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-12 15:41:15 [updated_time] => 2025-12-22 11:35:26 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-partners-with-Hanoi-hospital-of-andrology-and-infertility-to-host-the-december-prenatal-class [title] => Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prenatal class [description] => The journey of pregnancy is a sacred experience, one filled with unique emotions for every mother. It is the overwhelming joy of discovering the presence of a beloved baby, the day-by-day anticipation of feeling those first tiny movements, and at the same time, countless questions and concerns about health, nutrition, labor, and newborn care. [content] =>Understanding these concerns, Eurofins GENTIS is proud to partner with the Hanoi Hospital of Andrology and Infertility (AF HANOI) to organize the Prenatal Class – The Journey to Happy Motherhood, offering expectant mothers a warm, supportive space to gain knowledge and meaningful connection.
A special space for expectant mothers – where the journey to motherhood becomes sweeter
The prenatal class is not simply a session on pregnancy knowledge; it is a place where mothers-to-be and fathers-to-be can find reassurance, support, and love. It is an opportunity for future parents to prepare a solid foundation together before welcoming their little angel.
AF HANOI and Eurofins GENTIS aim to create a gentle, friendly learning environment where every mother feels comfortable sharing her concerns and receiving guidance from leading experts in obstetrics and gynecology.
Expert participation – the highlight of the Prenatal Class
At this session, expectant mothers will have the opportunity to listen to practical and valuable professional insights from two experienced doctors:
-
Dr. Nguyen Thi Hong Nhung, MD – Specialist in Obstetrics & Gynecology
-
Dr. Dam Dinh Tam, MD – Specialist in Obstetrics & Gynecology
With many years of experience accompanying pregnant women, these experts will deliver a friendly, practical, and informative session, helping young parents better understand fetal development and the changes in the mother’s body throughout pregnancy.
Prenatal Class – The journey to happy motherhood includes a wide range of topics, such as:
Essential knowledge on prenatal care
Mothers will be guided on appropriate nutrition, gentle exercises, proper health monitoring, warning signs to watch for, and ways to care for mental well-being to stay positive throughout the nine months and ten days of pregnancy.
Understanding labor and achieving a safe delivery
From signs of labor and bodily changes, to proper breathing and pushing techniques, and preparing a hospital bag—everything will be explained in detail by doctors to help mothers feel more confident during this important moment.
Scientific newborn care from the very first days of life
Caring for a newborn is always a major challenge, especially for first-time mothers. In the class, mothers will learn essential basics such as proper breastfeeding, bathing a baby, and handling common newborn issues.
Comprehensive Q&A from A to Z
Beyond passive learning, expectant mothers can ask doctors questions directly. Any concern—no matter how small—will be answered thoughtfully and thoroughly by the experts.
AF HANOI and Eurofins GENTIS hope to spread a sense of calm and reassurance to all participating mothers. Therefore, each mother will receive a small gift as a wish for a healthy pregnancy and a gentle, fulfilling motherhood journey.
Event Information
Time: 09:30 – 11:00, Saturday, December 27, 2025
Venue: 5th Floor Auditorium – Hanoi Hospital of Andrology and Infertility
Register now: forms.gle/kn6tj49GxxyqjbZy5
Or scan the QR code in the image to secure your seat early!
Seats are limited to ensure the quality of the class, so expectant mothers are encouraged to register early to avoid missing out.
Eurofins GENTIS – Accompanying mothers through every loving moment
Eurofins GENTIS deeply values every mother’s journey and believes that when mothers are well prepared with knowledge and emotional readiness, pregnancy becomes the most beautiful and peaceful time of life. By partnering with AF HANOI in this prenatal class, GENTIS hopes to bring mothers:
-
Peace of mind in every decision
-
Proactive confidence throughout pregnancy
-
Love that reaches babies from the very first days of life
Throughout a mother’s journey—from preconception, through pregnancy, to early childcare—Eurofins GENTIS is always ready to support with advanced genetic testing solutions, ensuring comprehensive and science-based care for both mother and baby.
In just one morning, mothers gain knowledge, connection, confidence, and love. That is the goal of the prenatal class and the values Eurofins GENTIS wishes to share.
Wishing all mothers a safe, healthy, and happiness-filled pregnancy.
[content_more] => [meta_title] => Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prena [meta_description] => The journey of pregnancy is a sacred experience, one filled with unique emotions for every mother. It is the overwhelming joy of discovering the presence of a beloved baby, the day-by-day anticipation of feeling those first tiny movements, and at the same [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1392 [category_id] => 4 ) [4] => stdClass Object ( [id] => 1391 [id_crawler] => [category_product] => NULL [thumbnail] => 580472851_1241583017989313_4603897227992683883_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-11-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-12 14:43:52 [updated_time] => 2025-12-22 14:48:06 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-congratulates-the-25th-French–Vietnamese-congress-of-obstetrics-and-gynecology-2025-on-its-great-success [title] => Eurofins GENTIS congratulates the 25th French–Vietnamese congress of obstetrics and gynecology 2025 on its great success [description] => Over two days, November 9–10, 2025, at the National Convention Center, the 25th French–Vietnamese Congress of Obstetrics and Gynecology 2025 jointly organized by the National Hospital of Obstetrics and Gynecology (NHOG) and the French National College of Gynecologists and Obstetricians (CNGOF)—was held with remarkable success. The congress welcomed more than 1,500 delegates, including leading experts, physicians, scientists, and research institutions from Vietnam and abroad. This prestigious scientific event marked over 25 years of strong and enduring collaboration between Vietnam and France in obstetrics and gynecology, reproductive health, and maternal and child care. [content] =>This year’s congress was not only a large-scale academic forum, but also an opportunity for professionals to update the latest knowledge, share practical experience, and foster collaboration aimed at improving the quality of medical care in Vietnam.
Eurofins GENTIS is honored to accompany the congress as a sponsor
As a pioneer in medical genetic testing, Eurofins GENTIS was proud to accompany the 25th Vietnam–France Congress of Obstetrics and Gynecology as a sponsor. Participation in this important event provided a valuable opportunity for GENTIS to reaffirm its position while connecting with the professional community to disseminate modern scientific and technological values to physicians, researchers, and hospitals nationwide.
Amid the growing demand for genetic testing and reproductive support, Eurofins GENTIS is committed to delivering accurate, safe, and rapid testing services to customers and partners, leveraging advanced technologies from the Eurofins Group—one of the world’s leading laboratory networks.
Exhibition Booth – A Highlight of the Congress
At the congress, Eurofins GENTIS introduced a modern exhibition booth and in-depth consultation area, presenting comprehensive solutions in genetics and reproductive medicine. The most highly regarded services included:
- Non-Invasive Prenatal Testing (NIPT)
A solution that analyzes cell-free fetal DNA in maternal blood to enable early detection of chromosomal aneuploidies, ensuring absolute safety for both mother and baby. - Preimplantation Genetic Testing (PGT)
PGT techniques help select genetically healthy embryos prior to uterine transfer, improving IVF success rates and reducing the risk of inherited diseases. - Genetic Disease Detection and Carrier Screening, Pre-marital and Preconception Counseling
Designed for couples preparing for marriage or pregnancy, helping to minimize risks associated with recessive genetic disorders. - Andrology Testing and Other Specialized Tests
Including sperm DNA fragmentation analysis, semen quality assessment, and services supporting infertility and subfertility treatment.
The Eurofins GENTIS booth attracted a large number of congress participants. Many domestic and international experts engaged in direct professional discussions with the GENTIS specialist team. These exchanges opened up valuable collaboration opportunities, promoting broader clinical application of modern genetic technologies in Vietnam.
In addition to its professional exhibits, GENTIS also organized interactive minigames with attractive prizes, creating a lively and friendly atmosphere—an activity warmly welcomed by many delegates.
Supporting the Scientific Presentation by Associate Professor Dr. Trinh The Son
One of the most notable scientific sessions at the congress was the presentation by Associate Professor Dr. Trinh The Son, Director of the Military Institute of Clinical Embryology, entitled “Genetics in Assisted Reproduction: Advances and Future Directions.” Eurofins GENTIS was honored to provide state-of-the-art genetic testing information for this valuable scientific report.
In his presentation, Associate Professor Dr. Trinh The Son highlighted major advances in genetics applied to assisted reproduction, ranging from chromosomal analysis and gene sequencing technologies to optimize embryo selection strategies in IVF.
He particularly emphasized the practical value of advanced tests such as PGT-Next, PGT-Upgrade, WES (Whole Exome Sequencing), and WGS (Whole Genome Sequencing). These techniques are currently implemented by Eurofins GENTIS in accordance with international standards, supporting physicians and patients in achieving higher success rates in infertility treatment.
The presentation received strong attention from the professional community, offering fresh perspectives on trends in applying genetics to modern reproductive medicine.
The Mark of a Successful Congress
After two dynamic working days, the 25th French–Vietnamese Congress of Obstetrics and Gynecology 2025 left a lasting impression. Beyond its academic success with dozens of high-quality scientific presentations, the event demonstrated a strong spirit of international collaboration, promoting exchanges between Vietnamese and French experts toward a shared goal: improving the quality of reproductive healthcare for the community.
The success of the congress stands as clear evidence of the Vietnamese obstetrics and gynecology sector’s continuous efforts to access new knowledge, technologies, and advanced global treatment standards.
Eurofins GENTIS extends its warmest congratulations to the Organizing Committee, experts, speakers, and all delegates who contributed to a vibrant, professional, and meaningful congress. We believe that the values, knowledge, and directions shared at this year’s event will continue to drive the development of obstetrics and gynecology in Vietnam, enabling more families to access advanced, safe, and effective medical solutions.
In the time ahead, Eurofins GENTIS will continue to accompany physicians, hospitals, and assisted reproduction centers nationwide, delivering high-quality testing services that meet international standards—contributing to the enhancement of reproductive health for the Vietnamese community.
[content_more] => [meta_title] => Eurofins GENTIS congratulates the 25th French–Vietnamese congress of obstetrics and gynecology 2025 [meta_description] => Over two days, November 9–10, 2025, at the National Convention Center, the 25th French–Vietnamese Congress of Obstetrics and Gynecology 2025 jointly organized by the National Hospital of Obstetrics and Gynecology (NHOG) and the French National College of [meta_keyword] => GENTIS,Conference [thumbnail_alt] => [post_id] => 1391 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1388 [id_crawler] => [category_product] => NULL [thumbnail] => 600x400-web-1.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-08 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-08 09:05:03 [updated_time] => 2025-12-10 15:48:02 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-participates-in-HASAM-2025-annual-scientific-conference-with-two-in-depth-reports-on-genetics [title] => Eurofins GENTIS participates in HASAM 2025 annual scientific conference with two in-depth reports on genetics [description] => The demand for reproductive healthcare is rising, and assisted reproductive technologies (ART) continue to advance rapidly. As a result, specialized scientific conferences play a crucial role in updating knowledge, strengthening professional networks, and improving treatment outcomes. The HASAM 2025 Annual Scientific Conference once again affirms its position as one of the most reputable professional events in Vietnam in the field of infertility and reproductive medicine. [content] =>Key highlights
With the theme “Updates on Scientific and Technical Advances to Improve Treatment Outcomes in Infertility”, the conference took place on December 14, 2025, at the National Convention Center (Hanoi), featuring 27 in-depth presentations and the participation of leading experts, doctors, researchers, and representatives from major IVF centers nationwide.
Eurofins GENTIS – a pioneering unit in genetic testing in Vietnam – was honored to accompany the event, aiming to contribute practical scientific value and bring more opportunities to couples hoping to have children.
HASAM 2025 – A prestigious scientific forum for Vietnam’s assisted reproduction field
Over the years, the Annual Scientific Conference of the Hanoi Assisted Reproduction Society (HASAM) has become a meeting place for the IVF community in Vietnam to exchange knowledge, share expertise, and update the latest scientific insights.
This year’s conference places strong emphasis on innovations in assisted reproduction, including:
-
Policies and development directions for assisted reproduction in Vietnam
-
Updates on ESHRE 2025 guidelines for ovarian stimulation
-
Advances in genetic screening, AI applications, and microfluidic technology
-
Optimization of treatment outcomes and individualized IVF protocols
-
Population aging and insights from reproductive medicine specialists
The presence of 27 specialized presentations painted a comprehensive picture of the latest scientific trends, contributing to the sustainable, internationally aligned development of ART in Vietnam.
Eurofins GENTIS proudly contributes two in-depth reports at HASAM 2025
As a member of Eurofins Scientific—a global leader in laboratory testing with more than 900 laboratories in 62 countries—Eurofins GENTIS consistently focuses on raising quality standards and developing advanced genetic applications for infertility treatment.
At HASAM 2025, Eurofins GENTIS presented two specialized reports, demonstrating its strong commitment to research and innovation:
-
Dr. Nguyenn Quang Vinh (Laboratory Director, Eurofins GENTIS): Comprehensive Quality Management of Genetic and Genomic Laboratories in Assisted Reproduction
-
Dr. Pham Dinh Minh (R&D Director, Eurofins GENTIS): Application of AI and Bioinformatics in Preimplantation Genetic Testing (PGT-AI)
Eurofins GENTIS booth – A space for knowledge exchange and genetic technology
Alongside its presentations, Eurofins GENTIS showcased an engaging exhibition booth that attracted widespread attention from experts and attendees. Visitors were introduced to a comprehensive ecosystem of genetic testing services in:
-
Assisted Reproduction: PGT-A/SR, PGT-M (100+ rare diseases), PGT-Upgrade, PGT-Next, Karyotype, …
-
Obstetrics: NIPT, double test, triple test, GEN9, preeclampsia screening,...
-
Andrology: Sperm DNA fragmentation, AZF testing, CFTR, …
-
Clinical Genetics: Genetic disease panels, comprehensive gene panels, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS)
The booth also featured an exciting mini-game program with various gifts for delegates visiting the Eurofins GENTIS area. It served as a space for in-depth discussions between Eurofins GENTIS experts and doctors, embryologists, and IVF specialists from centers across the country.
Through this activity, Eurofins GENTIS aims to promote scientific value, share knowledge, and accompany the medical community in improving reproductive healthcare quality in Vietnam.
Commitment to enhancing Vietnamese health and well-being
With the mission “Improving the Intelligence and Physical Well-being of Vietnamese People”, Eurofins GENTIS continuously strives to apply modern technologies in genetic testing to meet the increasing needs of assisted reproduction, providing practical value that helps couples increase their chances of welcoming healthy babies.
Its participation in HASAM 2025 once again reaffirms Eurofins GENTIS's commitment to supporting the medical community, advancing research, and bringing cutting-edge technologies closer to Vietnamese people.
Eurofins GENTIS respectfully invites doctors, experts, and attendees to visit our booth at HASAM 2025 on Sunday, December 14, 2025, at the National Convention Center, Hanoi.
[content_more] => [meta_title] => Eurofins GENTIS participates in HASAM 2025 annual scientific conference with two in-depth reports on [meta_description] => The demand for reproductive healthcare is rising, and assisted reproductive technologies (ART) continue to advance rapidly. As a result, specialized scientific conferences play a crucial role in updating knowledge, strengthening professional networks, and [meta_keyword] => GENTIS,Hasam 2025 [thumbnail_alt] => [post_id] => 1388 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1387 [id_crawler] => [category_product] => NULL [thumbnail] => ivf08616.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-12-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-04 08:33:25 [updated_time] => 2025-12-04 14:44:05 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => EUROFINS-GENTIS-conducts-technical-collaboration-at-Dong-Do-hospital-updates-on-ASEM-testing-in-assisted-reproduction [title] => EUROFINS GENTIS conducts technical collaboration at Dong Do hospital: updates on ASEM testing in assisted reproduction [description] => On November 28, the expert delegation from EUROFINS GENTIS, including Dr. Nguyen Quang Vinh (Director of the Genetic Counseling Center) and Dr. Pham Dinh Minh (Director of R&D), held a technical working session at Dong Do Hospital with the participation of the hospital’s reproductive medicine (IVF) team. This collaborative activity between EUROFINS GENTIS and Dong Do Hospital aimed to update the latest advances in genetic testing, thereby improving treatment outcomes for families struggling with infertility. The session not only facilitated academic exchange but also opened up new directions for long-term cooperation in the future. [content] =>The meeting was attended by Dr. Tang Duc Cuong (Specialist Level II) – Director of Dong Do IVF Center, MSc. Dr. Ngo Thi Diem – Head of the Obstetrics Department, along with physicians, nurses, and laboratory technicians from the hospital.
During the discussion, Dr. Nguyen Quang Vinh presented an overview of the cell-free DNA PGT (ASEM test), a non-invasive embryo culture medium-based genetic test currently attracting attention in the field of IVF. He explained that this technique analyzes cell-free DNA (cfDNA) released from embryonic cells through apoptosis or necrosis, originating from both the inner cell mass (ICM) and the trophectoderm. However, to ensure accuracy, it is crucial to completely eliminate maternal granulosa or cumulus cells, as contamination with exogenous DNA can significantly affect the results.
Dr. Vinh also addressed several studies comparing the concordance between cfDNA in the culture medium and traditional biopsy samples such as TE, ICM, or cord blood, providing a comprehensive view of the test’s clinical potential. He emphasized that laboratory procedures in the IVF unit play a decisive role in sample quality—from thoroughly removing surrounding cells after fertilization, changing culture medium on Day 3, washing embryos carefully on Day 4, to culturing embryos in a 20 µl drop from the afternoon of Day 4 to Day 5 for at least 22 hours to obtain sufficient DNA. When the embryo reaches Day 5/Day 6, the technician collapses the embryo and collects the entire medium into a PCR tube with a preservation buffer, ensuring tip changes between samples and storing at -20°C to -80°C before analysis.
The ASEM test can detect aneuploidies of 22 autosomes, large structural abnormalities greater than 40Mb, and can report mosaicism at levels of 50% or higher. Results are available within approximately 7 days. Based on analytical data, experts provided clinical suggestions such as considering the transfer of 46XX embryos, with 46XY embryos being more strongly recommended, while embryos carrying abnormalities such as -1q or -15 deletions are generally not advised for transfer. Dr. Vinh concluded by stressing that ASEM technology only delivers real value when embryo culture, washing, and medium collection processes in the IVF laboratory are meticulously executed, as precision in every step determines the reliability and clinical relevance of the test results.
The session provided in-depth knowledge and important updates, contributing to Dong Do Hospital’s application of advanced genetic technologies to improve the effectiveness of assisted reproductive treatments.
Beyond theoretical presentation, Dr. Nguyen Quang Vinh also addressed clinicians’ questions regarding real clinical cases. These detailed analyses helped the Dong Do medical team better understand the coordination process between the IVF laboratory, IVF center, and testing unit to optimize patient outcomes.
Continuing the session, Dr. Vinh emphasized EUROFINS GENTIS’s development direction in implementing new technologies, expanding collaboration with IVF centers, and enhancing testing quality according to international standards. Dong Do Hospital highly appreciated the expert team’s updated insights and reaffirmed its readiness to collaborate in improving assisted reproductive care.
Concluding the exchange, Dr. Tang Đuc Cuong expressed his gratitude to the EUROFINS GENTIS delegation. He highlighted that the updated knowledge on ASEM testing not only helps clinicians better understand the potential of modern genetic techniques but also opens new approaches for optimizing embryo selection in difficult IVF cases. He affirmed that Dong Do Hospital is committed to closely cooperating with EUROFINS GENTIS to standardize procedures, enhance sample quality, and progress toward adopting ASEM as an important clinical support tool in the near future. According to Dr. Cương, this partnership will bring practical benefits to patients, especially infertile couples hoping for a chance to become parents.
The session concluded in an open and collaborative atmosphere. The event reaffirmed EUROFINS GENTIS’s commitment to providing precise, modern, and effective testing solutions, contributing to increasing the chances of parenthood for thousands of Vietnamese families.
Case 1
The abnormality was discovered when a foreign man came to Eurofins Gentis to undergo an administrative father–child DNA test for birth registration and citizenship procedures. Based on the documents provided by the customer, the father was 36 years old, the child was a 5-month-old male, and the mother was a 20-year-old Vietnamese woman.
The testing was conducted according to standard procedures, and the results confirmed that the tested man and the child had a biological father–son relationship. The unusual point lay in the child’s sex. When analyzed using the 24-marker PowerPlex Fusion Kit, including Amelogenin and DYS391 for sex differentiation, the child’s genotype showed only XX at Amelogenin and no allele at DYS391, indicating a female genotype (see Peak image).
To establish a basis for concluding a sex abnormality, the company coordinated with the family to carry out a clinical examination, which confirmed that the child’s phenotype was male with clearly developed external genitalia.
Additionally, another test was performed to ensure accuracy: an analysis of the Y chromosome using the PowerPlex Y23 Kit. The results showed no Y-haplotype alleles at all (see Peak image).
Based on these findings, the company’s scientific council concluded that the child had 46, XX male syndrome (also known as XX Male Syndrome).
The cause of this phenomenon is unequal crossing-over between the Y chromosome and the X chromosome during the father’s meiosis. As a result, the X chromosome carries the SRY gene (the sex-determining gene). This occurs at the terminal region of the short arms of the X and Y chromosomes, where the SRY gene is normally located on the Y chromosome. When an X chromosome containing SRY combines with a normal maternal X chromosome at fertilization, it produces a 46, XX male genotype.
46, XX male syndrome occurs in approximately 1 in 20,000 newborn males, and individuals with this syndrome are infertile.
Case 2
A 42-year-old man visited the company with his 4-year-old son to request an administrative DNA test for father–son relationship verification. When asked why he wanted the test, he said he had a feeling the boy was not his because the child did not resemble him or his paternal relatives. His suspicion was emotional rather than factual—for accuracy, only DNA testing could provide an answer. Every customer has their own reasons for testing, often impossible to fully express.
Two days later, the results were completed. When he returned and learned that he and the boy were not biologically related, he fell silent for a moment, thanked the staff, and left.
About a week later, he returned again—this time with a prepared sample, stating it belonged to his 7-year-old daughter, and requested a comparison with his earlier sample. The results were astonishing: the daughter also had no biological relationship with him. Thus, both children he had tested were not his biological offspring.
Given the complicated circumstances, the scientific council analyzed the case carefully, especially because the Peak data at sex-related markers showed abnormalities. They decided to conduct an additional analysis using an X-test kit. The results revealed that the man had an XXY genotype, also known as Klinefelter syndrome (see Peak image).
The Peak chart clearly showed a male genotype (XY) at Amelogenin. However, most X-STR markers displayed two alleles (heterozygous), indicating two X chromosomes, while some X-STR markers showed a single peak (homozygous).
Klinefelter syndrome (XXY) occurs in males due to an extra X chromosome—typical males have XY. The syndrome arises randomly during gamete formation due to nondisjunction of sex chromosomes during meiosis. It occurs in approximately 1 in 500–1000 newborn males.
Males with XXY syndrome are typically infertile. Therefore, the fact that neither child was biologically related to him is understandable, and only the children’s mother would know who their biological father truly is.
Colonel Hà Quốc Khanh
[content_more] => [meta_title] => Detecting sex abnormalities through paternity testing [meta_description] => In medicine, research on sex abnormalities in both males and females has produced many scientific publications based on different research and testing methods, not only after birth but even during pregnancy. [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1383 [category_id] => 4 ) )
Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in Vietnam
Eurofins GENTIS operates throughout New Year’s day 2026
Preimplantation genetic testing: A key to improving IVF success and protecting future generations
Eurofins GENTIS partners with Hanoi hospital of andrology and infertility to host the december prenatal class
Eurofins GENTIS congratulates the 25th French–Vietnamese congress of obstetrics and gynecology 2025 on its great success
Eurofins GENTIS participates in HASAM 2025 annual scientific conference with two in-depth reports on genetics
EUROFINS GENTIS conducts technical collaboration at Dong Do hospital: updates on ASEM testing in assisted reproduction
Detecting sex abnormalities through paternity testing
Please fill in the information below to receive our supports and consultations!
Please fill in the information below to receive our supports and consultations!
